Mirum Pharmaceuticals price target raised to $69 from $68 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Mirum Pharmaceuticals to $69 from $68 and keeps a Buy rating on the shares post the Q3 results.